Low Dose Naltrexone for Treatment of Multiple Sclerosis... (Abstract)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability

J Clin Gastroenterol
October 2015
https://pubmed.ncbi.nlm.nih.gov/26203498/

This chart review focused on 215 MS patients who were provided a prescription for oral LDN. The study reports that a significant number of patients found combination therapy of an immunomodulating agent and LDN to be tolerable and possibly beneficial. Some patients preferred to take LDN as a monotherapy. The LDN did not cause any unexpected side effects, and those reported were previously noted in the literature. The LDN did not potentiate the side effects of the immunomodulating therapies that the patients were receiving.